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Tumor cell extravasation is a key step during cancer
metastasis, yet the precise mechanisms that regulate
this dynamic process are unclear. We utilized a high-
resolution time-lapse intravital imaging approach to
visualize the dynamics of cancer cell extravasation
in vivo. During intravascular migration, cancer cells
form protrusive structures identified as invadopodia
by their enrichment of MT1-MMP, cortactin, Tks4,
and importantly Tks5, which localizes exclusively
to invadopodia. Cancer cells extend invadopodia
through the endothelium into the extravascular
stroma prior to their extravasation at endothelial junc-
tions.Geneticorpharmacological inhibitionof invado-
podia initiation (cortactin), maturation (Tks5), or func-
tion (Tks4) resulted in an abrogation of cancer cell
extravasation and metastatic colony formation in an
experimentalmouse lungmetastasismodel. This pro-
videsdirect evidenceof a functional role for invadopo-
dia during cancer cell extravasation and distant
metastasis and reveals an opportunity for therapeutic
intervention in this clinically important process.
INTRODUCTION
Metastasis is a complex multistep process that represents the
most deadly aspect of cancer. Tumor cells that successfully
disseminate from the primary tumor and survive in the vascular
system eventually extravasate across the endothelium to colo-
nize secondary sites. However, the process of cancer cell extrav-
asation is the least understood step in the metastatic cascade.
Immune cell extravasation, or diapedesis, relies on ligand-recep-
tor interactions for adhesion to the endothelium, forming special-
ized structures called podosomes to facilitate their transit across1558 Cell Reports 8, 1558–1570, September 11, 2014 ª2014 The Authe endothelial layer (Carmanet al., 2007).Morphologically, these
podosomes have been described as ‘‘invadosome-like protru-
sions’’ that are thought to be the normal counterparts of subcel-
lular protrusions that are commonly referred to as invadopodia in
cancer cells (Carman and Springer, 2004; Carman et al., 2007;
Murphy and Courtneidge, 2011). Podosomes have been
observed in vivo during atherogenesis of the intimal layer of
mouseaorta (Quintavalleet al., 2010) and inneural crestmigration
during embryonic development (Murphy et al., 2011), yet a phys-
iological role for invadopodia in cancer has not been established.
Invadopodia are cancer-specific protrusive and adhesive
structures that were initially observed in vitro as shallow protru-
sions on the basolateral side of cultured cancer cells. Extensive
efforts to characterize invadopodia and podosomes have re-
vealed that they are composed of structural proteins such as
cortactin, N-WASP, Tks4, and Tks5 (Clark et al., 2007; Murphy
and Courtneidge, 2011; Oser et al., 2009; Weaver et al., 2002).
Of these, Tks5 is exclusively present within podosomes, sug-
gesting that it plays a specific role in invadopodia formation
andmaturation (Abram et al., 2003; Seals et al., 2005). Invadopo-
dia concentrate proteases such as MT1-MMP, MMP9, and
MMP2 for local directed release and/or activity during extracel-
lular matrix breakdown (Clark et al., 2007), and Tks5 is required
in both invadopodia and podosomes to degrade matrix in vitro
(Caldieri et al., 2009; Furmaniak-Kazmierczak et al., 2007; Mag-
alhaes et al., 2011; Pignatelli et al., 2012; Seals et al., 2005).
The visualization of cancer cell invadopodia in living organisms
has been elusive due to the challenges associated with distin-
guishing them fromother invasive structures such as lamellipodia
(Gligorijevic et al., 2012). Although established components of in-
vadopodia such as cortactin, MT1-MMP, and Tks4 are also ex-
pressed in other protrusive structures including lamellipodia,
recent evidence suggests that invadopodia canbe specifically in-
hibited through loss of function of Tks5 (Burger et al., 2014; Diaz
et al., 2009; Sharma et al., 2013a). Cytoplasmic extensions
formed by tumor cells during intravascular arrest in capillary
beds have been observed in zebrafish models (Stoletov et al.,thors
Figure 1. CapillaryPlexus, Endothelium, and
Endothelial Junction Organization in the
Avian Embryo Chorioallantoic Membrane
(A) Lectin-rhodamine labels the luminal surface of
endothelial cells and junctions (yellow), whereas
dextran-FITC fills the lumen (L) of the capillary bed
(green). Scale bar represents 10 mm.
(B) CAM endothelium and endothelial junctions
labeled with lectin-rhodamine (red) presented in
three different Z planes, top of CAM, CAM plexus,
and bottom of CAM. Endothelial junctions are
pseudocolored in green. Arrows denote repre-
sentative endothelial junctions. Scale bar repre-
sents 5 mm.
(C) CAM endothelial cells (E) transduced by i.v.-in-
jected lentivirus encoding zsGreen with endothelial
junctions labeled by lectin-rhodamine at various
Z planes. Endothelial junctions are identified by
white arrows that border the two zsGreen-positive
endothelial cells. Scale bar represents 10 mm.2010; Yamauchi et al., 2006), yet a functional link to extravasation
has not been established. The visualization and characterization
of invadopodia formation inmodelsof breast cancer (Kedrin et al.,
2008; Roh-Johnson et al., 2014) have suggested invadopodia as
key mediators of intravasation (Eckert et al., 2011; Gligorijevic
et al., 2012). Invadopodia have been observed in ex vivo experi-
ments (Schoumacher et al., 2010; Weaver et al., 2013), providing
additional support for a role in vivo. However, despite mounting
evidence that invadopodia are prevalent inmetastatic tumor cells
and play a key functional role in the invasion and metastasis of
cancer, direct evidence for their contribution in vivo is lacking.
Given the involvement of podosomes in immune cell extravasa-
tion and the prevalence of invadopodia in metastatic tumor cells,
we sought to investigate the role that invadopodia might play in
cancer cell extravasation in vivo. To visualize these dynamic cell
interactions in high-resolution detail in real time, we utilized an
intravital microscopy platform specifically developed to investi-
gate cancer cellmigration in vivo using the exovo chicken embryo
model (Arpaiaetal., 2012;Leongetal., 2010,2012a, 2012b). In this
report, we use real-time 3D time-lapse intravital imaging to visu-Cell Reports 8, 1558–1570, Sepalize the behavior and dynamics of cancer
cell extravasation in vivo. We provide
direct evidence of the role of invadopodia
during cancer cell extravasation. We
demonstrate that disruption of invadopo-
dia assembly via interference with struc-
tural proteins such as cortactin, Tks4 and
Tk5, either by genetic or pharmacological
means, results in decreased extravasation
efficiencyandanabrogationofmetastasis.
RESULTS
Intravital Imaging of Human Cancer
Cells and Endothelium in Ex Ovo
Chicken Embryos
The chorioallantoic membrane (CAM) of
the chicken embryo, with its highlyorganized capillary bed network supported by arteries, veins,
and stromal cells, is an ideal model to visualize the behavior
of disseminating human tumor cells in vivo (Deryugina and
Quigley, 2008; Koop et al., 1996). For these studies, an
intravital microscopy platform capable of capturing high-reso-
lution 3D time-lapse imagery of human tumor growth, cell
migration, and extravasation using the ex ovo chicken embryo
model was utilized (Arpaia et al., 2012; Goulet et al., 2011;
Leong et al., 2012a, 2012b; Palmer et al., 2014; Zijlstra et al.,
2008). Visualization of the luminal surface of the CAM endo-
thelium is achieved upon intravenous (i.v.) injection of fluores-
cent Lens culinaris agglutinin (Figure 1A, yellow; Movie S1),
which interacts specifically with the glyocalyx of avian endo-
thelial cells (Jilani et al., 2003). Blood volume is visualized using
i.v. fluorescent dextran (Figure 1A, green; Movie S1). Extravas-
cular regions of the CAM, populated by stromal cells, are
readily identified during intravital imaging by their lack of
lectin-rhodamine staining (Figure 1A, red arrows). As we have
observed previously (Arpaia et al., 2012), a significant accumu-
lation of lectin-rhodamine staining is observed at endothelialtember 11, 2014 ª2014 The Authors 1559
Figure 2. Intravascular Migration of Cancer Cells within the Capillary Bed of the Avian Embryo CAM
(A) HEp3-GFP cell (green) labeled with Hoechst (blue) arrested within the capillary bed. XZ and YZ views of each image are shown for each channel (top and side
orthogonal images, respectively; scale bar represents 10 mm.
(B) HEp3-GFP cells undergo intravascular amoeboid migration until they begin projecting protrusions into the extravascular stroma at 70min postinjection. Scale
bars represent 25 mm. The top depicts cells within the intravascular plane, and the bottom represents cells protruding into extravascular stroma. An afferent
arteriole that is highlighted in red in the top also represents the large vessel present in the bottom.
(C) HEp3-GFP cell arrested within the CAM forms fan-like projections into the CAM plexus. Scale bar represents 15 mm.
(D) A single intravascular HEp3-GFP cell in the CAMprojects protrusions into the intravascular space (small white arrows) and a larger protrusive structure through
the endothelium into the adjacent stroma (arrowhead). Scale bar represents 7 mm.junctions during intravital imaging experiments (Figure 1B;
Movie S2, white arrows, junctions pseudocolored green),
allowing their precise delineation. To confirm this, the avian
endothelium was transduced with cytoplasmic zsGreen in
vivo using i.v. lentivirus prior to injection of lectin-rhodamine,
which resulted in cytoplasmic GFP expression in roughly 5%
of the CAM endothelial cells (Figure 1C). Strong lectin stain-
ing corresponded precisely with the endothelial cell-cell junc-
tions when examined using multiple Z views (white arrows,
Figure 1C).1560 Cell Reports 8, 1558–1570, September 11, 2014 ª2014 The AuCancer Cells Undergo Intravascular Migration Prior to
Extravasation
To define the characteristics of tumor cell arrest and extravasa-
tion in this model, time-lapse intravital imaging was performed
after the i.v. injection of fluorescent human epidermoid carci-
noma (HEp3-GFP) cells into the vitelline vein of ex ovo chicken
embryos preinjected with lectin-rhodamine. Circulating tumor
cells initially arrest at the distal end of CAM arterioles where
they meet the capillary plexus (Figures 2A and 2B, red pseudo-
colored vessel). Cancer cells conform to the vascular lumenthors
and adopt an amoeboid morphology, maintaining close contact
with the endothelium during intravascular migration (Figure 2B,
top), before extravasating into the adjacent stromal layer of the
CAM (Figure 2B, bottom; Movie S3). During this process, highly
dynamic cytoplasmic protrusions are observed at the leading
edge of intravascular HEp3-GFP cells (Figure 2C). Although
the majority of these dynamic protrusions are intravascular
(Figure 2D, small white arrows), a proportion of these extend
through the endothelium into the adjacent stroma (Figure 2D,
arrowhead).
CancerCells Form InvasiveCytoplasmicExtensions that
Breach the Endothelium
Intravital imaging of the early stages of cancer cell extravasa-
tion revealed that cancer cells form cytoplasmic protrusions
that extend through the endothelium into the extravascular
stroma. We observed that cells typically migrate intravas-
cularly along the endothelium for 6–8 hr and then cease migra-
tion (Figure 3A, t = 0 hr panel). At this point, protrusions
(Figure 3A, t = 0.25 hr panel, yellow arrow; Movie S4) are
observed that cross the endothelium into the extravascular
stroma. Figure 3B is a full Z projection of an individual cell un-
dergoing extravasation, highlighting the transition of the intra-
vascular (grayscale) and extravascular portions (green) over
time. At t = 1.25 hr, the cell has begun extravasation and
over the next 3 hr, the extravascular portion (green) grows
larger, whereas the intravascular portion (white) gradually
shrinks as the cell translocates from the vessel into the stroma
(Movie S5). Figure 3C depicts a single cancer cell forming two
distinct protrusions (pink and blue arrows) into the extravas-
cular stroma (bottom). However, in all cases observed, cancer
cells follow a single protrusion to complete extravasation.
These invasive structures were observed in a substantial frac-
tion of a panel of cancer cells, as quantified by intravital imag-
ing (Figure 3D).
The precise route of extravasation was also investigated
using high-resolution intravital imaging. When individual planes
of 3D image volumes from extravasating HEp3-GFP cells
(Figures S1A and S1B) were examined, it was clear that the
majority of invasive protrusions project through endothelial
junctions that have separated slightly, and that these separa-
tions resolve once extravasation is completed (Figure S1D). A
panel of cancer cell lines including HT1080 (fibrosarcoma),
B16F10 (melanoma), MDA-MB-231LN (breast), and T24
(bladder) were evaluated and found also to extravasate mainly
at endothelial junctions (Figure S1C). In some cases, we
observed that the cancer cells extensively remodeled the
local endothelium, appearing to displace endothelial cells to
gain access to the extravascular stroma (Figure S1E). In
these cases, the endothelial cells remained viable but did not
resolve in the time frame of our experiments. No evidence of
interendothelial transit was observed (Carman and Springer,
2008).
Cancer Cells Project Invadopodia through the
Endothelium during Cancer Cell Extravasation
We hypothesized that components of invadopodia were pre-
sent within the cytoplasmic protrusions of extravasating cancerCell Recells observed in vivo. Histology was performed on frozen
cross-sectional slices of CAM containing extravasating
HT1080 fibrosarcoma cells (Figure 4A). Visualized by fluores-
cence microscopy, extravasating cells had protrusions (Fig-
ure 4A, second panel, white arrows) projecting through the
endothelial layer (L, dotted line) and extending into the extra-
vascular stroma (ES). These cell protrusions contain both
F-actin (Figure 4A, third panel) and cortactin (Figure 4A, fourth
panel), indicating that these protrusive structures might be
invadopodia.
To further characterize the identity and dynamics of these
protrusions during extravasation, structural components known
to be localized or concentrated in invadopodia such as cortac-
tin, Tks4, and Tks5 (Buschman et al., 2009; Oser et al., 2010;
Sung et al., 2011; Abram et al., 2003; Seals et al., 2005) were
assessed in extravasating cancer cells using intravital imaging.
Constructs encoding the fusion proteins cortactin-zsGreen
(CTTN-zsG) and Tks4-zsGreen (Tks4-zsG) were stably trans-
fected into three aggressive human cancer cell lines: epider-
moid carcinoma HEp3, fibrosarcoma HT1080 (HT1080-tdT),
and breast cancer MDA-MB-231LN (231LN-tdT). The localiza-
tion of each of these was confirmed using fluorescence imag-
ing (Figure S2).
During extravasation of 231LN-tdT cells in vivo, cortactin-
zsGreen was abundant in cytoplasmic protrusions extending
through the endothelium (Figures 4B and 4C). Although cortac-
tin-zsGreen is also present in foci throughout the cell, the cyto-
plasmic extension extending into the stromal layer (Figure 4B,
bottom; inset) contains organized structures of cortactin-
zsGreen that would be expected in invadopodia. Localization
of cortactin-zsGreen in HEp3 cells was present as diffuse
puncta throughout the cell and within thin invasive structures
at the point of extravasation (Figure 4C, arrow). A significant
enrichment in cortactin-zsGreen was observed within protru-
sions that extended through the endothelium (Figure 4C,
arrow).
Localization of Tks4-zsG in HEp3, HT1080-tdT and 231LN-
tdT cell lines was also evaluated during extravasation using
intravital imaging. In intravascular 231LN-tdT breast cancer
cells, Tks4-zsGreen was present as diffuse signal throughout
the cytoplasm (Figure 4D, upper left; Movie S6). During extrava-
sation, however, Tks4-zsGreen localized to the apical tips of
cytoplasmic protrusions extending into the CAM stroma (Fig-
ure 4D, upper right; Figure 4D, bottom, white arrow; Movie
S6). The localization of Tks5-GFP, in contrast, was concentrated
at the base of and throughout the protrusion invading into the
extravascular stroma (Figure 4E; Movie S7). A similar concentra-
tion at the base of invadopodia was not observed in cells
expressing Tks4-zsG. The proteolytic activity of MT1-MMP
is a key marker of invadopodia, and it was also observed in pro-
trusions formed by extravasating 231LN-tdT cells (Figure 4F)
and HT1080 cancer cells (Figure 4G) expressing MT1-MMP-
GFP. The enrichment of cortactin, Tks4, Tks5, and MT1-MMP
in these invasive protrusions suggests that they are indeed
invadopodia, and our intravital imaging experiments suggest
that cancer cells extend invadopodia between endothelial
cells and into the extravascular stroma prior to and during
extravasation.ports 8, 1558–1570, September 11, 2014 ª2014 The Authors 1561
Figure 3. The Formation of Invasive Protrusions Precedes Cancer Cell Extravasation
(A) Formation of invadopodia (yellow arrows) projecting through the endothelial layer (red arrows and red dashed line) into extravascular stroma. Within 15 min
(right), a significant protrusion has formed that has projected through the endothelial layer (red arrows and red dashed line). Scale bars in XY and XZ views are
20 mm, whereas scale bar in YZ is 4 mm.
(B) HEp3-GFP cell undergoing extravasation. Green signal represents portion of cell that has extravasated. White signal represents portion of cell
that remains within the intravascular space. Invadopodia formation is highly dynamic within the extravascular stroma (red arrows). Scale bar represents
20 mm.
(legend continued on next page)
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Tks4, Tks5, and Cortactin Are Required for Invadopodia
Formation and Extravasation in the CAM
To understand the impact of invadopodia on extravasation
in vivo, we performed loss-of-function experiments targeting
Tks4 and Tks5 individually, which has been shown to inhibit inva-
dopodia function in vitro (Buschman et al., 2009; Diaz et al.,
2009). We hypothesized that RNAi knockdown of Tks4 or Tks5
would inhibit invadopodia formation in cancer cells, thus abro-
gating cancer cell extravasation and metastasis. Cancer cell
lines with stable small hairpin RNA (shRNA) knockdowns of cor-
tactin (Figure S3A), Tks4, and Tks5 (Figures S3C and S3D) were
evaluated for their ability to form invadopodia, to extravasate,
and to establish metastatic colonies in vivo. These were
compared with cells lacking key cell migration mediator RhoA
(Figure S3B).When assessed for their ability to degrade extracel-
lular matrix, loss of cortactin, but not RhoA, reduced the fraction
of cells able to degrade gelatin (Figure S3E).
HEp3-GFP cells expressing RhoA or cortactin shRNAs were
assessed in extravasation assays with the chick embryo CAM
using an intravital imaging approach. Cancer cells arrested in
the CAM were visualized (Figures 5D–5F) and classified accord-
ing to their location as intravascular (Figure 5G), in the process of
extravasating (Figure 5H), or extravascular (Figure 5I). Themajor-
ity of shLuc HEp3-GFP cells (40%–50%) extravasate within
24 hr (Figure 5I), with very few cells present in the intravascular
space (Figure 5G). In contrast, a significantly greater proportion
of shCTTN cells remained in the intravascular space at each time
point, whereas very few shRhoA cells were present within the
intravascular space (Figure 6G). Moreover, very few shRhoA
and shCTTN cells successfully extravasated after 24 hr after
i.v. injection (Figure 5I). Because the numbers of extravasating
cells can be monitored over time in each embryo, the number
of cells that have been lost/died can be determined (Figure 5J).
Cells expressing shRhoA exhibited the greatest loss between
the t = 0 to t = 6 hr time points, indicating that most of these cells
likely died in the intravascular space. Cell attrition was much
lower in the first 6 hr for shLuc and shCTTN cells, indicating
that the significant difference in the numbers of intravascular
and extravascular cells after 24 hr was not due to cell death,
but due to an inhibition of the shCTTN cells to successfully
extravasate.
The impact of cortactin on subsequent metastatic colony for-
mation was then assessed using intravital imaging and an exper-
imental metastasis approach. Two hundred thousand cells/
embryo were injected i.v., and after 7 days the number of metas-
tases (Figure 5A), micrometastases (Figure 5B), and single can-
cer cells (Figure 5C) present throughout the entire CAM organ
was enumerated. Embryos injected with shRhoA and shCTTN
cells had the fewest metastases, micrometastases, and single
cells compared to both parental and shLuc control cells. Taken
together, these data indicate that RhoA depletion inhibits meta-
static colony formation primarily through cell attrition, whereas
the inhibition of invadopodia through the depletion of cor-(C) A single T24-zsGreen cell undergoing extravasation. The top depicts a single c
extravascular stroma (bottom).
(D) Fraction of cells that form invadopodia as observed using intravital imaging d
Error bars represent ± SEM.
Cell Retactin inhibits metastasis as a result of decreased cancer cell
extravasation.
Although Tks4 is predominantly localized to invadopodia, it
has also been observed within lamellipodia, whereas Tks5 has
only been observed in invadopodia (Abram et al., 2003; Busch-
man et al., 2009; Seals et al., 2005). To further establish the
requirement of invadopodia for extravasation and metastatic
colony formation, 231LN-tdT cell lines with stable shRNA knock-
downs for Tks4 and Tks5 (Figures S3C and S3D) were evaluated
for their ability to extravasate in the CAM of avian embryos over a
24 hr time period. 231LN-tdT cells lacking RhoA, CTTN, Tks4, or
Tks5 had significantly decreased extravasation rates compared
to control cells (Figure 5K). Furthermore, these were also
observed to have decreased incidence of protrusions formed
by cells arrested in the intravascular space (Figure 5L) 3 hr after
i.v. injection of cells. Collectively, this provides strong evidence
that invadopodia are indeed required for efficient extravasation
in the CAM. These in vivo loss-of-function experiments demon-
strate a requirement for CTTN, Tks4, and Tks5 in the formation of
invadopodia and cancer cell extravasation.
Src Kinase Inhibition Abrogates Invadopodia Formation
and Extravasation
Src kinase regulates invadopodia formation via phosphoryla-
tion of cortactin to its active state (Evans et al., 2012; Mader
et al., 2011; Oser et al., 2009), while also phosphorylating a
number of other targets (Ferrando et al., 2012). Treatment of
HEp3-GFP cells with the Src kinase inhibitor Saracatinib at
1.0 mM significantly altered in vitro cell morphology from a stel-
late to cobblestone morphology (Figures 6A and 6B). A marked
reduction of cortactin-rich invadopodia and the associated
adhesion-type structures that are characteristic of invadopodia
was observed (red arrowheads, Figures 6C and 6D). The
impact of Src kinase inhibition on the extravasation kinetics
of HEp3-GFP cells in the avian embryo CAM was assessed
in vivo over a 24 hr time period, comparing Saracatinib at
1.0 mM versus vehicle. No in vivo or in vitro cytotoxic effects
were observed when Saracatinib was administered to a final
concentration of 1.0 mM (Figure S6). Saracatinib-treated cancer
cells at 3–6 hr after i.v. injection exhibited a significant
decrease in invadopodia formation compared to vehicle-
treated cells (Figure 6E). Over 24 hr, Saracatinib treatment re-
sulted in significantly decreased extravasation rates compared
to vehicle control at t = 24 hr (Figures 6G and 6H) accompanied
by a retention of Saracatinib-treated cells in the intravascular
space at t = 24 hr (Figure 6F). The interpretation of the data
is complicated somewhat by the fact that more Saracatinib-
treated cells were lost or died in the first 3 hr compared to
vehicle-control-treated cells (Figure 6I), resulting in significantly
fewer cells successfully extravasating at after 24 hr. Neverthe-
less, these data suggest that Saracatinib directly impacts can-
cer cell extravasation, providing a potentially useful therapeutic
approach.ell forming two different cytoplasmic protrusions (pink and blue arrows) into the
uring extravasation in a panel of cancer cell lines (n = 50 cells, three animals).
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Figure 4. The Formation of Cortactin and Tks4-Positive Invadopodia Precedes Cancer Cell Extravasation in Vivo
(A) Representative HT1080-tdT cells in the CAM that are intravascular (left) or undergoing extravasation (middle). A cross-section of CAM with no cells is also
shown (right). The second panel of images shows a single HT1080-tdT cell with a cytoplasmic extension that has projected through the endothelium (labeled with
lectin-FITC, green). The dotted line demarcates the extravascular stroma-capillary bed interface. L, capillary bed lumen; ES, extravascular stroma. The third panel
shows a single HT1080-tdT cell that has formed a cytoplasmic extension that contains F-actin. The fourth panel shows cytoplasmic extensions formed by a single
HT1080-tdT cell that contains cortactin, an invadopodia-specific marker. Scale bars represent 5 mm.
(B) Intravital imaging of a single 231LN-tdT cell prior to extravasation with a CTTN-zsG-rich protrusion (inset).
(C) Intravital imaging of a single CTTN-zsG-expressing HEp3 cell undergoing extravasation into the extravascular stroma. Themultilobed structure present within
the extravascular stroma has a cortical distribution of CTTN-zsG.
(legend continued on next page)
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Inhibition of Tks4 or Tks5 Reduces Metastatic Colony
Formation in a Mouse Lung Metastasis Model
Given our observations in the chicken embryo CAM model, we
sought to confirm our findings in a mammalian adult cancer
model. Clonogenic MDA-MB-231LN-tdT cell lines were gener-
ated with stable shRNA knockdowns for Tks4 and Tks5 (Figures
S3C and S3D) and evaluated for their ability to extravasate and
form metastatic colonies in murine lungs following tail vein injec-
tion in nude beigemice. Extravasation efficiencywas determined
by comparing the number of cells that extravasated at t = 24 hr
after i.v. injection to the number of cells that initially arrested in
the lung at t = 0 hr after i.v. injection. According to histological
sections of injectedmurine lungs, themajority of cells were intra-
vascular immediately after injection (Figures 7A and 7C, open
bars), and all cells that were present in the lungs after 24 hr
had successfully extravasated as determined by confocal micro-
scopy (Figures 7B and 7C, filled bars). Knockdown of Tks4
or Tks5 resulted in significant decreases in extravasation
compared to shLUC control (Figure 7C). Indeed, the majority of
the Tks4 and Tks5 shRNA clones exhibited negligible rates of
extravasation, with no extravasated cancer cells visible 24 hr
after injection. Metastatic burden was also evaluated at 4 weeks
postinjection, where knockdown of Tks4 or Tks5 resulted in a
significant decrease in the number of macrometastases (Fig-
ure 7D), micrometastases (Figure 7E), and extravascular single
cells (Figure 7F). Representative thick-mount sections of lung
metastases formed by i.v. injection with the 231LN-tdT shLUC
control cells or 231LN-tdT cells expressing the Tks4 or Tks5
shRNA knockdown construct can be found in Figures S4 and
S5. Altogether, these data demonstrate in two xenograft models
of human cancer metastasis that invadopodia are required for
extravasation and metastatic colonization of distant sites.
DISCUSSION
The extravasation of cancer cells at distant sites occurs predom-
inantly within capillary beds (Chambers et al., 2002) and is
thought to be a key step in the metastatic cascade, preceding
metastatic colony formation. During the past several years, a pu-
tative role for invadopodia in cancer cell migration and invasion
has been extensively described using in vitro approaches (Artym
et al., 2006; Buschman et al., 2009; Diaz et al., 2009; Linder,
2007; Mader et al., 2011; Oser et al., 2009), whereas a lack of
direct in vivo evidence for invadopodia has raised questions
regarding their physiological relevance in cancer. Using cortac-
tin, MT1-MMP, and Tks4/5 fusion expression constructs and
shRNA-mediated knockdown, we have determined that invado-(D) Single MDA-MB-231-tdT cell expressing Tks4-zsG that is predominantly i
concentrated at the tip of the cytoplasmic extension, which has extended into the
3D-rendered images of this cell (red) from above and below the CAM capillary end
invadopodium that is extending into the extravascular stroma.
(E) An individual MDA-MB-231LN-tdT cell expressing Tks5-GFP has compartm
invading into the extravascular stroma (S, dotted line). Scale bars represent 10 m
(F) An individual MDA-MB-231LN-tdT cell expressing MT1-MMP-GFP has comp
cular stroma (red arrows).
(G) HT1080 cells expressing MT1-MMP-GFP (green) project protrusions through t
are expanded in the right, and a line scan is provided in order to show that MT1-M
endothelium and beyond the endothelium in the extravascular stroma.
Cell Repodia are formed early in the extravasation process, manifest as
protrusions that project through the endothelial layer, and are
required for successful extravasation. Cancer cell extravasation
is a highly coordinated and dynamic process that occurs within
24 hr, consistent with observations mademany years ago during
our initial intravital imaging experiments (Koop et al., 1996). Inhi-
bition of the structural or functional components of invadopodia
results in a significant decrease in metastatic colony formation in
two experimental models of metastasis. By providing direct ev-
idence of the functional importance of invadopodia in cancer
cell extravasation in vivo, these studies demonstrate that invado-
podia play a crucial role in the metastatic cascade and represent
a potential therapeutic target for antimetastasis strategies.
The assembly of invadopodia is a tightly regulated and
sequential process that is characterized by the initial formation
of nondegradative invadopodium precursors that are enriched
in actin regulators, including cortactin, Arp2/3, and cofilin among
others (Clark et al., 2007; Oser et al., 2009). These precursors
then mature through a sequence of events that involve stabiliza-
tion through Tks5 interactions (Blouw et al., 2008), actin polymer-
ization, and the recruitment of matrix proteases such as
MT1-MMP, whose localization and stability is further regulated
by factors such as Tks4 (Buschman et al., 2009). This results in
mature, matrix-degrading invadopodia that coordinate the re-
modeling of the ECM topromote cell migration and translocation.
Based on our observations regarding the ability of invadopodia to
project through the endothelial layer in the early steps of cancer
cell extravasation, we hypothesized that their inhibition would
prevent extravasation and the subsequent formation of
metastatic colonies. We investigated the inhibition of distinct
steps of invadopodia initiation (cortactin), maturation (Tks5),
and function (Tks4) on the extravasation of metastatic cancer
cells and compared these to the loss of RhoA, which would be
expected to inhibit cell migration in an invadopodia-independent
way. Extravasation rateswere significantly decreased in theCAM
of the avian embryo andmouse lungs when any of these contrib-
utors to invadopodiawere depleted in cancer cells. The depletion
of Tks4 or Tks5 in cancer cells also led to a decrease inmicrome-
tastases and single cells compared to control cancer cells,
suggesting that the inhibition of invadopodia has additional anti-
metastatic effects that lead to a further decrease in metastatic
efficiency. These observations are consistent with other studies
that have established a role for invadopodia in other steps in
the metastatic cascade, such as tumor growth and intravasation
(Blouw et al., 2008; Gligorijevic et al., 2012; Sharma et al., 2013b),
and implicates these structures in a generalmechanism for tumor
cell motility and translocation.ntravascular but has begun the process of extravasation (left). Tks4-zsG is
adjacent extravascular stroma (right). Scale bars are XY, 10 mm, and XZ, 3 mm.
othelium (magenta) show localization of Tks4-zsG (green) at the apical tip of the
entalized the majority of Tks5-GFP signal within the invadopodia, which is
m.
artmentalized MT1-MMP-GFP in protrusions that are present in the extravas-
he endothelium (red) into the extravascular stroma (black). Invasive protrusions
MP expression is localized in the protrusion both at the site of contact with the
ports 8, 1558–1570, September 11, 2014 ª2014 The Authors 1565
Figure 5. Knockdown of Cortactin and
RhoA Results in Decreased Extravasation
Efficiency
(A–F) (A) The total number of overt metastases
(more than five cells), (B) micrometastases (two to
five cells), and (C) single cells found throughout the
CAM at 5 days postextravasation. In (A)–(C), *p <
0.05 compared to shLUC. One-way ANOVA with
Bonferroni test. n = 8 per group. Representative
HEp3-GFP cells imaged within the intravascular
space (D), in the process of extravasation (E), and
immediately postextravasation (F).
(G–J) White bars denote shLuciferase HEp3-GFP
cells. Gray bars denote shRhoA HEp3-GFP cells.
Black bars denote shCTTN HEp3-GFP cells. (G)
The percentage of cells present within the intra-
vascular space over a 24 hr time frame. *p < 0.05
compared to shLUC and shRhoA. xp < 0.01
compared to shRhoA. (H) The percentage of cells
observed to be actively in the process of extrava-
sation. (I) The percentage of cells present within
the extravascular stroma. *p < 0.01 compared to
shLUC and shRhoA. (J) The percentage of cells
lost/died at each 6 hr time frame throughout the
24 hr time frame of analysis. *p < 0.001 compared
to shLUC and shCTTN. In (G)–(J), experiments
consisted of n = 3, >400 cells per animal. Two-way
ANOVA with Bonferroni test was used for (G)–(J).
(K) Extravasation efficiency assay of MDA-MB-
231LN-tdT cells with shLUC (white bar), shRhoA,
shCTTN, and shTks4/5 (black bars) over a 24 hr
time course. * p < 0.01 compared to shLUC, n >
100 cells counted for each animal, n > 5 for each
group.
(L) Quantitation of protrusions formed by intra-
vascular arrested cells in K) at 3 hr after i.v. injec-
tion of cells. *p < 0.01 compared to shLUC, n > 50
cells counted for each animal, n > 5 for each group.
Error bars represent ± SEM.We have established that the inhibition of extravasation by
targeting invadopodia is a viable antimetastasis approach. None-
theless, a clinical window of opportunity for antimetastatic thera-
pies may not exist for all cancer patients, especially considering
the primary tumor’s ability to disseminate cancer cells into the cir-
culation at early stages of progression. However, there may be
therapeutic opportunities at distinct stages of cancer develop-
mentand treatment that areworthyof additional study.Asubstan-
tial body of clinical evidence suggests cancers with an extended
natural history, such as prostate cancer, acquire metastatic po-
tential during the course of progression. Thus, some benefit1566 Cell Reports 8, 1558–1570, September 11, 2014 ª2014 The Authorsfrom antimetastasis agents might be
realized for patients that are identified at
increased risk of metastasis (Palmer
et al., 2014). Additionally, a therapeutic
approach targeting extravasation directly
couldbeevaluated for cancers that require
neoadjuvant treatment to reduce the size
of the tumor for subsequent surgical
resection, offering the opportunity to also
interfere with extravasation of cancer cellsshed during treatment. Finally, based on growing evidence that
cancer cells are shed into the circulation subsequent to core-nee-
dle biopsy (Hansen et al., 2004) or surgery (Juratli et al., 2014), it
would beworth exploring whether an antiextravasation approach
could help to mitigate any potential risk from these procedures.
Our understanding of cancer cell extravasation has been
informed to a significant extent by well-characterized mecha-
nisms of immune cell transendothelial migration or diapedesis.
This study both clarifies and substantiates our concepts of can-
cer cell extravasation through the dynamic visualization of indi-
vidual cancer cells at high resolution. Although the processes
Figure 6. Saracatinib, a Src Kinase Inhibitor,
Decreases Cancer Cell Extravasation In Vivo
(A) Representative confocal laser scanning micro-
graph of HEp3-GFP cells immunostained with an-
tibodies specific for human cortactin (CTTN).
(B) Treatment with Saracatinib (1 mM final) shows a
lack of cortactin-rich membrane ruffles and adhe-
sion-type structures.
(C) High magnification of cortactin-rich membrane
adhesion-type structures formed by HEp3-GFP
cells.
(D) Saracatinib treatment results in the loss of
adhesion-type structures formed by HEp3-GFP
cells.
(E) Saracatinib inhibits invadopodia formation
in vivo over a 3 hr time frame prior to extravasation
(n > 200 cells per group).
(F–I) Extravasation efficiency assay using HEp3-
GFP cells treated with vehicle (white bars) and
1 mM Saracatinib (black bars). The percentage of
cells present within the intravascular space (F), in
the process of extravasation (G), within the extra-
vascular stroma (H), and the percentage of cells
lost/died between each time frame (I). *p < 0.05
compared to vehicle treatment. xp < 0.001
compared to vehicle treatment. One-way ANOVA
with Bonferroni test. &p < 0.05 compared to
vehicle treatment at t = 0, Student’s t test.
Error bars represent ± SEM.of cancer cell extravasation and leukocyte diapedesis share
several common features (Carman and Springer, 2008), we did
not see any evidence in our intravital imaging experiments that
cancer cells undergo transcellular migration, or migration
through pores created in endothelial cells, as seen with leuko-
cytes. Our examination of thousands of cells from a panel of can-
cer cell lines undergoing extravasation demonstrated clearly that
cancer cells in this model system utilize a paracellular route of
transendothelial migration into the extravascular stroma. The
simplest explanation for this is due to the fact that cancer cells
are typicallymuch larger in volume than leukocytes or endothelial
cells.Wedid observe that aminority of extravasating cells gained
access to the extravascular stroma by amore dramatic displace-
ment of endothelial cells. This did not appear to impact theCell Reports 8, 1558–1570, Sepviability of the endothelial cells and is
consistent with previous observations in
an in vivo model (Stoletov et al., 2010)
that suggests that tumor cells can play
an active role in remodeling the local
endothelium. This is particularly inter-
esting in light of a recent report that links
invadopodia biogenesiswith the secretion
of exosomes (Hoshino et al., 2013). In our
intravital imaging experiments, invadopo-
dia were quite dynamic in morphology as
they extended into the extravascular
stroma and were sporadically associated
with the transient release of microparti-
cles. The idea that invadopodia utilize atightly regulated microvesicle release mechanism to influence
the local microenvironment is a compelling one and warrants
further investigation. Overall, we have established a powerful
model to visualize and dissect the key functional and structural
components of invadopodia and provide unequivocal evidence
for a role for invadopodia during cancer cell extravasation.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents
Thehumanepidermoidcarcinomacell lineHEp3, humanbreast cancer cell lines
MDA-MB-435, MDA-MB-468, MDA-MB-231-luc-D3H2LN (termed MDA-MB-
231LN or 231LN), fibrosarcoma cell line HT1080, and human bladder cancer
cell line T24 were all maintained as described previously (Leong et al., 2012a;
Vantyghem et al., 2005; Zijlstra et al., 2008). Lectin-Rhodamine/Fluoresceintember 11, 2014 ª2014 The Authors 1567
Figure 7. Invadopodia-Specific Tks4 and
Tk5 Are Required for Extravasation and the
Formation of Metastases
(A) Representative MDA-MB-231LN-tdT cell ar-
rested within a microvessel as identified by Lectin-
FITC and Phalloidin-A647 reveals stroma.
(B) Extravasated cell present within lung stroma.
(C) Extravasation efficiency of MDA-MB-231LN-
tdT cells with shLUC, shTks4, or shTks5 knock-
down constructs in the mouse lung. White bars
represent 231LN cells observed in a random field
in mouse lung sections at t = 0, and the black bars
represent the number of 231LN cells observed in
mouse lung sections at t = 24 hr. *p < 0.05
compared to shLUC t = 24 hr, two-way ANOVA,
Bonferroni test. n = 5mice per cell line at each time
point.
(D–F) (D) The number of macrometastases
(more than 50 cells observed in single colony),
micrometastases (E), and single cells (F) pre-
sent in mouse lung sections from mice i.v.
injected with 231LN cells with shLUC, shTks4,
and shTks5 knockdown constructs. *p < 0.05
compared to shLUC, one-way ANOVA. For
(D)–(F), n = 8 mice were used for each cell type/
shRNA clone.
Error bars represent ± SEM.conjugates (Lens culinaris Agglutinin, Vector Laboratories) and Wheat Germ
Agglutinin-Alexa 647 (Invitrogen) were diluted 20 times with 1 3 PBS (pH 7.4).
Vectors pzsGreen-C1 (Clontech) and pTdTomato (kindly provided by
Dr. Roger Tsien, UCSD) were stably transfected into cancer cell lines with
Superfect (QIAGEN). Cortactin and luciferase shRNA constructs were kindly
provided by Dr. Jason Moffat and the Ontario Institute for Cancer
Research (OICR) Genomics Facility. The Src kinase inhibitor Saracatinib
(AZD0530) was provided by AstraZeneca and diluted into 10 mM stocks
with DMSO and then diluted with PBS for injections. Antibodies specific for
cortactin, Tks4, and Tks5 were from Cell Signaling Technology and phalloidin-
A647 was from Invitrogen. The cortactin cDNA was acquired from the OICR
Genomics Facility. Cortactin and Tks4 coding regions were PCR amplified
without the stop codon and inserted within the BamH1-Age1 site of the
pzsGreen-C1 vector (Clontech). Primers were designed such that an Ala-Ala-
Leu-Pro-Val-Ala-Thr (A-A-L-P-V-A-T) linker was engineered between the target
and the zsGreen coding sequence. The ALPVAT linker is endogenous to the
original surrogate vector.
The Ex Ovo Chick Embryo Model for Visualization of Cancer Cell
Extravasation and Metastasis
To label the luminal surface and endothelial junctions within the CAM, 50 ml
of Lectin-Rhodamine/Fluorescein or Wheat Germ Agglutinin-A647 was intra-1568 Cell Reports 8, 1558–1570, September 11, 2014 ª2014 The Authorsvenously injected using a disposable micropipette
syringe as described previously (Leong et al.,
2012b). After 10 min of lectin microinjection, can-
cer cells were injected and imaged as described
previously (Leong et al., 2012a). The experimental
metastasis assays were performed as described
previously (Zijlstra et al., 2008). Volocity software
(Perkin-Elmer) was used for the acquisition of
4D data sets and used in combination with
ImageJ (NIH) for image analysis. To label the
cytoplasm of individual endothelial cells within
the CAM, 75 ml of zsGreen-encoding lentivirus
was injected into D9 avian embryos and then sub-
sequently injected at D14 with 50 ml of Lectin-Rhodamine to label endothelial junctions. ZsGreen-lentivirus was generously
provided by Dr. Jason Moffat.
Histology of Cancer Cell Extravasation In Vivo
Histology of cancer cells undergoing extravasation was performed by intrave-
nous injection of lectin-fluorescein and 53 106 HT1080-tdT cells into the CAM,
and tissue was removed and fixed in formalin + 25% sucrose overnight. CAM
tissue was embedded in OCT for frozen sectioning at 5 mm thickness. For
immunohistochemistry of CAM cross-sections with HT0180-tdT cells under-
going extravasation, anti-CD44 monoclonal antibody (mAb) (clone 29-7) was
used for primary antibody staining followed by goat anti-mouse immunoglob-
ulin (Ig) G-HRP secondary antibody staining. The anticortactin mAb and its
secondary antibody stain, goat anti-mouse IgG-Alexa 594, and phalloidin-
Alexa 647 were used to stain for invadopodia in cancer cells.
Quantitative RT-PCR and Western Immunoblot Analysis
Total RNA was extracted from trypsinized cells with Trizol (Invitrogen). RNA
(1 mg) was reverse transcribed into cDNA by random priming using the One-
Step RT-PCR Kit (QIAGEN). Quantification of cDNA was done using SYBR
Green Supermix for real-time qPCR (Bio-Rad) with oligonucleotide sequences
that specifically recognize GAPDH, RhoA, cortactin, Tks4, and Tks5. GAPDH
was used as a control for total cDNA. Samples for western immunoblot
analysis were prepared by lysing 2 3 106 cells of interest with 200 ml of RIPA
buffer (0.05% protease inhibitor cocktail, Roche Scientific) and incubating
on ice for 15 min, centrifugation of samples at 4C at 8,000 3 g for 10 min,
reserving the protein lysate supernatant for SDS-PAGE. After protein quantita-
tion by Bio-Rad protein assay reagent using BSA as a standard, 20 mg of
protein was loaded and submitted to SDS-PAGE electrophoresis on 8%
SDS-PAGE gels and transferred onto a nitrocellulose membrane (Amersham).
Membranes were blocked in 5% skim milk in TBS-T and incubated with the
indicated primary antibody overnight at 4C. After multiple PBSwashes, mem-
branes were then incubated with horseradish peroxidase-conjugated second-
ary antibodies for 1 hr and then were detected using ECL plus western blotting
detection system (Amersham).
Avian Embryo CAM Extravasation Efficiency Assay
HEp3-GFP cells with cortactin, RhoA, or Luciferase shRNA knockdowns were
injected intravenously into the CAM (n > 5 per group) and the proportion of cells
in the intravascular space, in the process of extravasation and having extrava-
sated were enumerated in a marked 1 cm 3 1 cm area over a 24 hr period. At
t = 0 postinjection, all cells were assumed to be intravascular, and, at t = 6 and
t = 18, 75 ml of lectin-rhodamine (Vector Labs) was injected intravenously prior
to enumeration. Using spinning disk confocal microscopy, individual cells
were enumerated, and its phase (intravascular, process of, extravascular)
was determined at t = 6, 12, 18, and 24 hr postinjection. At least 100 cells
per region of interest were examined for each animal. Hep3-GFP cells were
also pretreated with 1 mM of Saracatinib overnight prior to injection into the
CAM (n > 5 per group), and the proportion of cells in each plane (intravascular,
process of, extravascular) was evaluated as described above with the cells
submitted to shRNA knockdown. For metastatic colony formation endpoint
assays, cells were also injected intravenously into CAMs (n R 8 per group)
and the evaluated at t = 7 days postinjection. The number of macrometastatic
colonies (>20 cells), micrometastatic colonies (<20 and greater than two cells),
and single cells were enumerated across the entire CAM of the avian embryo.
Mouse Experimental Metastasis Lung Assay and Extravasation
Efficiency Assay
MDA-MB-231LN cells with Tks4/5 or Luciferase shRNA knockdowns were in-
jected intravenously in tail veins of 8-week-old female nude beige mice. To
evaluate extravasation efficiency, 2.5 3 105 of each cell line was injected
(n = 5 each time point/group), and lungs were harvested t = 24 hr postinjection.
One hundred microliters of Griffonia simplicifolia agglutinin-1-fluorescein
isothiocyanate (FITC) (GSA-1-FITC, 103 dilution in PBS, Vector Labs) was in-
jected prior to lung harvesting. To evaluate metastatic colony formation, 2.53
105 of each cell line was injected (n = 8 per group), and lungs were harvested
4 weeks postinjection. All mouse lungs were fixed in formaline + 25% sucrose
overnight. Frozen sections of all harvested lungs consisted of 5-mm-thick sec-
tions taken every tenth section. Phalloidin-Alexa 647 was also used alongside
the GSA-1-FITC signal to distinguish extravasated cells from intravascular
cells within the lung tissue. For extravasation efficiency analysis, slides were
also stained with Hoechst 33258 (2500X dilution) for 10 min prior to mounting
with ProLong Gold (Invitrogen). In all other cases, ProLong Gold + DAPI
(Invitrogen) was used to mount all tissues. All animals (nude beige mice, avian
embryos) were housed, maintained, and treated by procedures approved by
University of Western Ontario and London Health Sciences Centre Institutional
Animal Care and Use Committees (IACUC).
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